Collegium Pharmaceutical (COLL) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Geron (GERN) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 11.6% versus a loss of 33.3%. Over five years, COLL leads with a +5.4% price change compared with -13.5% for GERN. Geron is the larger company by market cap ($783.8 million vs $719.8 million), about 1.1 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 30.5x for Geron).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | GERN |
|---|---|---|
| Share price | $22.11 | $1.22 |
| Market cap | $719.80M | $783.82M |
| 1-day change | +0.82% | +1.67% |
| YTD return | -52.25% | -7.58% |
| 1-year return | -33.26% | -11.59% |
| 5-year return | +5.39% | -13.48% |
| P/E ratio (TTM) | 17.41 | — |
| Forward P/E | 3.33 | 30.50 |
| EPS (TTM) | $1.27 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $2.01 |
| 52-week low | $21.43 | $1.04 |
| Distance from 52-week high | -56.47% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.62% | +248.36% |
| Average volume | 749.33K | 10.07M |
| Shares outstanding | 32.56M | 642.47M |
| Employees | 423 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GERN has outperformed COLL by 21.7 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
COLL vs GERN FAQ
Which is bigger, Collegium Pharmaceutical or Geron?
Geron (GERN) is larger, with a market capitalization of $783.82M compared with $719.80M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or GERN?
GERN returned -11.59% over the past 12 months, compared with -33.26% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.